Similar articles

• Karyotype changes during long-term targeted therapy of chronic myeloid leukemia with imatinib.

  Pieńkowska-Grela B, Rygier J, Woroniecka R, Grygalewicz B, Pastwińska A, Krawczyk P, Ceglerek B, Seferyńska I, Sikorska A, Konopka L. Pieńkowska-Grela B, et al. Leuk Lymphoma. 2009 Jun;50(6):952-65. doi: 10.1080/10428190902838384. Leuk Lymphoma. 2009. PMID: 19479611
• Presence of complex t(6;9;22;15) four-way chromosome rearrangement plus rare t(1;6) translocation with favorable response to imatinib therapy in chronic myelogenous leukemia.

  Lu CM, Zhou L, Feng S, Kohn PH, Qi Z, Yu J. Lu CM, et al. Leuk Lymphoma. 2011 Nov;52(11):2182-4. doi: 10.3109/10428194.2011.585674. Epub 2011 Jun 30. Leuk Lymphoma. 2011. PMID: 21718138 No abstract available.
• Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.

  Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL, Arber DA, Slovak ML, Forman SJ. Bhatia R, et al. Blood. 2003 Jun 15;101(12):4701-7. doi: 10.1182/blood-2002-09-2780. Epub 2003 Feb 6. Blood. 2003. PMID: 12576334
• A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia.

  Griesinger F, Hennig H, Hillmer F, Podleschny M, Steffens R, Pies A, Wörmann B, Haase D, Bohlander SK. Griesinger F, et al. Genes Chromosomes Cancer. 2005 Nov;44(3):329-33. doi: 10.1002/gcc.20235. Genes Chromosomes Cancer. 2005. PMID: 16001431 Review.
• Chronic myelogenous leukemia.

  D'Antonio J. D'Antonio J. Clin J Oncol Nurs. 2005 Oct;9(5):535-8. doi: 10.1188/05.CJON.535-538. Clin J Oncol Nurs. 2005. PMID: 16235580 Review.